Meril Life Sciences Unveils One-Year Results from LANDMARK Trial

On November 21, 2025, at the PCR London Valves conference, Meril Life Sciences shared the one-year outcomes from its pivotal LANDMARK Randomized Controlled Trial (RCT). This trial is the first multicenter RCT comparing the balloon-expandable Myval THV series with Sapien and Evolut THV series in patients with aortic stenosis.

The results highlighted that the Myval THV series showed comparable efficacy with Sapien and Evolut, with 87% freedom from mortality, stroke, or hospitalization. Extended efficacy, including quality of life measures, also favored Myval at 80.5%. Notably, the Myval series recorded the lowest moderate aortic regurgitation at 1.6%.

Professor Patrick W. Serruys noted the Myval's reliable valve performance, supporting informed choices in TAVI procedures. Professor Andreas Baumbach emphasized the study's role in understanding valve performance under standard conditions. This trial sets a strong foundation for Myval's continued adoption globally.